These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 23749669)

  • 1. New therapeutic targets and drugs for the treatment of chronic hepatitis B.
    Fletcher SP; Delaney WE
    Semin Liver Dis; 2013 May; 33(2):130-7. PubMed ID: 23749669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of chronic hepatitis B: Evolution over two decades.
    Yuen MF; Lai CL
    J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():138-43. PubMed ID: 21199525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic hepatitis B: a treatment update.
    Wong VW; Chan HL
    Semin Liver Dis; 2013 May; 33(2):122-9. PubMed ID: 23749668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of HBeAg positive chronic hepatitis B: interferon or nucleoside analogues.
    Dusheiko G
    Liver Int; 2013 Feb; 33 Suppl 1():137-50. PubMed ID: 23286858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. On-treatment monitoring of chronic hepatitis B virus infection: an Asian-Pacific perspective.
    Chien RN
    J Gastroenterol Hepatol; 2010 May; 25(5):852-7. PubMed ID: 20546437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis B virus DNA and hepatitis B surface antigen levels in chronic hepatitis B.
    Fung J; Lai CL; Yuen MF
    Expert Rev Anti Infect Ther; 2010 Jun; 8(6):717-26. PubMed ID: 20521898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Why do I treat HBeAg-positive chronic hepatitis B patients with a nucleoside analogue.
    Ma H; Jia J
    Liver Int; 2013 Feb; 33 Suppl 1():133-6. PubMed ID: 23286857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on hepatitis B virus infection.
    You CR; Lee SW; Jang JW; Yoon SK
    World J Gastroenterol; 2014 Oct; 20(37):13293-305. PubMed ID: 25309066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term outcome of renal transplant recipients with chronic hepatitis B infection-impact of antiviral treatments.
    Yap DY; Tang CS; Yung S; Choy BY; Yuen MF; Chan TM
    Transplantation; 2010 Aug; 90(3):325-30. PubMed ID: 20562676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Global perspective on the natural history of chronic hepatitis B: role of hepatitis B virus genotypes A to J.
    Liu CJ; Kao JH
    Semin Liver Dis; 2013 May; 33(2):97-102. PubMed ID: 23749665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in the molecular diagnosis of hepatitis B infection: providing insight into the next generation of disease.
    Bayliss J; Nguyen T; Lesmana CR; Bowden S; Revill P
    Semin Liver Dis; 2013 May; 33(2):113-21. PubMed ID: 23749667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum hepatitis B surface antigen concentration correlates with HBV DNA level in patients with chronic hepatitis B.
    Su TH; Hsu CS; Chen CL; Liu CH; Huang YW; Tseng TC; Liu CJ; Chen PJ; Lai MY; Chen DS; Kao JH
    Antivir Ther; 2010; 15(8):1133-9. PubMed ID: 21149920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Telbivudine plus adefovir therapy for chronic hepatitis B patients with virological breakthrough or genotypic resistance to telbivudine.
    Zhang Y; Lian JQ; Li Y; Wang JP; Huang CX; Bai XF; Wang JP
    Eur J Gastroenterol Hepatol; 2013 Jul; 25(7):814-9. PubMed ID: 23406845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B.
    Reijnders JG; Perquin MJ; Zhang N; Hansen BE; Janssen HL
    Gastroenterology; 2010 Aug; 139(2):491-8. PubMed ID: 20381492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of acute hepatitis B and reactivation of hepatitis B.
    Jindal A; Kumar M; Sarin SK
    Liver Int; 2013 Feb; 33 Suppl 1():164-75. PubMed ID: 23286861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy.
    Kim HJ; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI
    J Gastroenterol Hepatol; 2010 Aug; 25(8):1374-80. PubMed ID: 20659226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Why do I treat HBeAg-negative chronic hepatitis B patients with nucleos(t)ide analogues?
    Papatheodoridis GV
    Liver Int; 2013 Feb; 33 Suppl 1():151-6. PubMed ID: 23286859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulatory T-cell responses in chronic hepatitis B patients treated with nucleos(t)ide analogs compared with healthy subjects and untreated infected individuals.
    Chen LY; Zhu LY; Yang BS; Bi MR; Yan BZ; Wang W; Ma YJ
    Hepatogastroenterology; 2012; 59(120):2582-6. PubMed ID: 22626879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic hepatitis B in Asia-new insights from the past decade.
    Chan HL; Jia J
    J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():131-7. PubMed ID: 21199524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis B surface antigen seroconversion is associated with favourable long-term clinical outcomes during lamivudine treatment in HBeAg-negative chronic hepatitis B patients.
    Idilman R; Cinar K; Seven G; Bozkus Y; Elhan A; Bozdayi M; Yurdaydin C; Bahar K
    J Viral Hepat; 2012 Mar; 19(3):220-6. PubMed ID: 22329377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.